NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

ESSENCE trial of Novo Nordisk's GLP-1 drug semaglutide shows efficacy in MASH, setting up filings in the US and Europe next year.

Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...

Weight loss jabs like Mounjaro may aid obesity treatment, but skipping crucial blood tests can trigger severe side ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...